ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals (OTCBB:RXHN) has been granted a US patent for its anti-sense compounds, including its leading oncology candidate, RX-0201. The patent covers the nucleotide sequences of the anti-sense compounds that target and inhibit the expression of human Akt-1 in human tissues or cells. The patent also covers the method of using the compounds to induce cytotoxicity in cancer cells. RX-0201 is a first-in-class anti-sense signal inhibitor that directly blocks the production of Akt, a protein kinase that plays a key role in cancer progression.
